Oral influenza vaccination with live attenuated viruses. 2. Protective efficacy during a type A(H3N2) epidemic.
151 subjects, orally immunized with live attenuated influenza virus of the Institute for Viral Preparations of Moscow (bivalent A(H3N2) England 72 and B vaccine) and 66 non vaccinated cohabitants were studied during an epidemic caused by strains similar to A/Port Chalmers/73. 5 cases of disease were virologically or serologically ascertained among the vaccinated (morbidity 3.3%) and 8 among the non-immunized cohabitants (12.1%). The difference turned out statistically significant. By comparing the incidence of the disease in the two groups the protection resulting from vaccination was 72.6%.
D000284:Administration, Oral; D004196:Disease Outbreaks; D006801:Humans; D053122:Influenza A Virus, H3N2 Subtype; D009980:Influenza A virus / Q000276:immunology; D007252:Influenza Vaccines / Q000008:administration & dosage*; D007251:Influenza, Human / Q000517:prevention & control*; D014611:Vaccination / Q000592:standards*; D014613:Vaccines, Attenuated
D007252:Influenza Vaccines; D014613:Vaccines, Attenuated